Suppr超能文献

无导线起搏器植入的早期趋势:评估全国范围内的住院治疗结局。

Early trends in leadless pacemaker implantation: Evaluating nationwide in-hospital outcomes.

机构信息

Department of Internal Medicine, University of Miami/Jackson Memorial Hospital, Miami, Florida.

Division of Cardiovascular Diseases, University of Miami/Jackson Memorial Hospital, Miami, Florida.

出版信息

Heart Rhythm. 2022 Aug;19(8):1334-1342. doi: 10.1016/j.hrthm.2022.04.008. Epub 2022 Apr 14.

Abstract

BACKGROUND

Single-chamber leadless intracardiac pacemaker (LICP) implantation was approved in 2016 in the United States. However, little is known regarding trends in real-world utilization and complication rates.

OBJECTIVE

The purpose of this study was to assess nationwide demographics, trends, and outcomes among hospitalizations with LICP implantation in the United States.

METHODS

Using the National Inpatient Sample, we identified all hospitalizations with LICP or transvenous pacemaker implantation as a comparator between 2017 and 2019. We evaluated baseline patient characteristics, admitting diagnoses, procedural complications, lengths of stay, discharge dispositions, and all-cause mortality.

RESULTS

The majority of LICP recipients were elderly (75.4 ± 12.8 years), male (55.2%), and White (76.8%) compared to Black (9.8%), or Hispanic (7.3%). Between 2017 and 2019, the average age increased along with the prevalence of heart failure, atrial fibrillation, and malignancy among recipients. Most hospitalizations were emergent (84.5%). Between 2017 and 2019, pooled procedural complications decreased significantly (10.8% vs 7.9%; P <.001), primarily due to declining infection and device retrieval rates. In-hospital mortality also decreased significantly (8.2% vs 4.2%; P <.001). History of cardiogenic shock or cardiac device infection was associated with the greatest mortality or complication risk. Compared to transvenous pacemaker, LICP implantation was associated with lower complication rates (8.6% vs 11.2%) but greater mortality (5.2% vs 1.3%; P <.001).

CONCLUSION

Nationwide LICP implantations were performed in patients of increasing age, comorbidities, and acuity of illness. In-hospital mortality and procedure-related complications declined in the first 3 years after approval of LICP implantation and may reflect improving operator experience. Increased mortality compared with transvenous pacemaker implant remains a concern.

摘要

背景

单腔无导线心脏起搏器(LICP)于 2016 年在美国获得批准。然而,对于其在真实世界中的应用趋势和并发症发生率知之甚少。

目的

本研究旨在评估美国 LICP 植入术住院治疗的全国人口统计学、趋势和结局。

方法

我们使用国家住院患者样本,确定了 2017 年至 2019 年期间所有 LICP 或经静脉起搏器植入术的住院患者。我们评估了患者的基线特征、入院诊断、程序并发症、住院时间、出院去向和全因死亡率。

结果

与黑人(9.8%)或西班牙裔(7.3%)相比,LICP 接受者多为老年人(75.4±12.8 岁)、男性(55.2%)和白人(76.8%)。在 2017 年至 2019 年期间,随着接受者中心力衰竭、心房颤动和恶性肿瘤的患病率增加,平均年龄也随之增加。大多数住院治疗是紧急情况(84.5%)。在 2017 年至 2019 年期间,总体程序并发症显著下降(10.8%对 7.9%;P<.001),主要是由于感染和设备取出率下降。院内死亡率也显著下降(8.2%对 4.2%;P<.001)。心源性休克或心脏设备感染史与最大的死亡率或并发症风险相关。与经静脉起搏器相比,LICP 植入与较低的并发症发生率(8.6%对 11.2%)相关,但死亡率较高(5.2%对 1.3%;P<.001)。

结论

全美范围内,年龄、合并症和疾病严重程度增加的患者接受了 LICP 植入术。在 LICP 植入术批准后的头 3 年内,院内死亡率和与程序相关的并发症下降,这可能反映了操作人员经验的提高。与经静脉起搏器植入相比,死亡率增加仍然令人担忧。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验